InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Posted by Brian Himes on Aug 8th, 2026

InflaRx (NASDAQ:IFRX – Get Free Report) posted its earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04), Zacks reports.

InflaRx Stock Performance

Shares of NASDAQ:IFRX traded up $0.12 on Friday, reaching $1.84. The company’s stock had a trading volume of 1,167,412 shares, compared to its average volume of 890,553. InflaRx has a 52-week low of $0.78 and a 52-week high of $2.95. The company has a market cap of $133.01 million, a P/E ratio of -3.17 and a beta of 2.48. The company has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $1.53.

Institutional Trading of InflaRx

Several hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC grew its holdings in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the last quarter. Boothbay Fund Management LLC boosted its position in shares of InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after buying an additional 17,056 shares during the period. Squarepoint Ops LLC boosted its position in shares of InflaRx by 29.1% during the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after buying an additional 42,489 shares during the period. HRT Financial LP bought a new position in shares of InflaRx during the fourth quarter valued at approximately $47,000. Finally, Insigneo Advisory Services LLC bought a new position in shares of InflaRx during the fourth quarter valued at approximately $61,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on IFRX. Oppenheimer initiated coverage on shares of InflaRx in a report on Friday, April 24th. They set an “outperform” rating and a $5.00 price objective for the company. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research upgraded InflaRx from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 27th. Guggenheim reissued a “buy” rating and set a $14.00 price target on shares of InflaRx in a research note on Tuesday, April 21st. Finally, Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Check Out Our Latest Stock Report on InflaRx

About InflaRx

(Get Free Report)

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.